Bullous Pemphigoid
Conditions
Brief summary
Bullous pemphigoid is the most common subepidermal autoimmune blistering disease of the skin in European countries, including France. Immunologically, BP is characterized by the production of autoantibodies directed against two major components of the hemidesmosome, BP180 and BP230. The anti-BP180 autoantibody is detected in 79-93% of cases of bullous pemphigoid and its serum level at diagnosis have been correlated with disease activity. The anti-BP230 autoantibody is detected in 57%-63% of bullous pemphigoid cases and its score at diagnosis did not correlate with disease activity. Up to now, no clinical or immunologic factors have been identified to predict outcome of patients with good or poor prognosis bullous pemphigoid as defined by long complete remission off therapy and recurrent disease requiring maintenance therapy for years. The usefulness of BP180 or BP230 ELISA scores for monitoring BP patients during treatment also remains unclear.
Detailed description
Aim of the study were : To study association between the serum level of cytokines (IL-17 and IL-23) and of the protease MMP-9 and the relapse of bullous pemphigoid.
Interventions
OTHERBlood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9
Sponsors
CHU de Reims
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients with bullous pemphigoid * patients not yet receiving treatment for bullous pemphigoid * aged \> 18 years
Exclusion criteria
\- Patients with relapse of bullous pemphigoid
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relapse of bullous pemphigoid. | Month 12 | The relapse of bullous pemphigoid is defined as he reappearance of at least 3 new daily blisters along with pruritus and/or erythematous, eczematous or urticarial plaques |
Countries
France
Outcome results
None listed